Results 101 to 110 of about 2,101 (161)

Comparative Efficacy of Janus Kinase Inhibitors (JAKis) for Ulcerative Colitis in Japanese Regional Healthcare Facilities: A Real-World Database Study. [PDF]

Cureus
Itoi Y, Hashimoto Y, Masuo T, Masuda T, Marubashi K, Iwamoto A, Sekiguchi M, Takahashi K, Kimura Y, Hachisu Y, Tomaru S, Sato K, Tanaka H, Hosaka H, Kuribayashi S, Takeuchi Y, Uraoka T.   +16 more
europepmc   +1 more source

Application of JAK inhibitors in the treatment of rheumatoid arthritis: a systematic analysis based on clinical trial databases and registries. [PDF]

Front Med (Lausanne)
Cao J, Huang R, Chen Y, Li X, Lou J, Xu L, Gu J, Luo Z, Yao T, Xie J.   +9 more
europepmc   +1 more source

The antitumor mechanism of oclacitinib in canine lymphoma. [PDF]

Sci Rep
Harada M, Inanaga S, Sakurai M, Shibutani S, Sugasawa T, Murayama N, Osumi T, Baba Y, Sakai H, Maeda S, Igase M, Mizuno T.   +11 more
europepmc   +1 more source

Computational identification of small molecules for increased gene expression by synthetic circuits in mammalian cells. [PDF]

Nat Commun
Pisani M, Calandra F, Rinaldi A, Cella F, Tedeschi F, Boffa I, Vozzi D, Brunetti-Pierri N, Carissimo A, Napolitano F, Siciliano V.   +10 more
europepmc   +1 more source

Kinetics of intestinal ultrasound and shear-wave elastography to assess early response in ulcerative colitis patients treated with filgotinib. [PDF]

J Crohns Colitis
Pruijt MJ, Teichert C, De Voogd FA, Janssen RJ, Löwenberg M, Goetgebuer RL, D'Haens GR, Gecse KB.   +7 more
europepmc   +1 more source

Effects of Janus Kinase Inhibitors on Rheumatoid Arthritis Pain: Clinical Evidence and Mechanistic Pathways. [PDF]

Biomedicines
Belančić A, Sener S, Sener YZ, Fajkić A, Vučković M, Markotić A, Benić MS, Potočnjak I, Pavlović MR, Radić J, Radić M.   +10 more
europepmc   +1 more source

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort. [PDF]

Rheumatol Ther
Celletti E, Di Penta M, Ariani A, Parisi S, Andracco R, Raffeiner B, Ianniello A, Lo Gullo A, Molica Colella AB, Priora M, Paroli M, Lumetti F, Ravagnani V, Girelli F, Vitetta R, Volpe A, Scolieri P, Bezzi A, Ometto F, Visalli E, Farina A, Del Medico P, Bravi E, Colina M, Larosa M, Serale F, Franchina V, Molica Colella F, Ferrero G, Sandri G, Addimanda O, Reta M, Mascella F, Focherini MC, Fiorenza A, Rovera G, Giampietro C, Bernardi S, Mansueto N, Camellino D, Caccavale R, Nucera V, Sabatini E, Del Biondo P, Ditto MC, Platè I, Adorni G, Di Donato E, Santilli D, Lucchini G, Amato G, De Lucia F, Dal Bosco Y, Foti R, Smerilli G, Bianchi G, Foti R, Arrigoni E, Marchetta A, Bixio R, Bruzzese V, Fusaro E, Giuggioli D, Salvarani C, Cipollone F, Becciolini A.   +65 more
europepmc   +1 more source

Factors Associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA): Real-World Evidence from a Single-Center Cross-Sectional Study. [PDF]

J Pers Med
Benucci M, Li Gobbi F, Cassarà EAM, Terenzi R, Cioffi E, D'Elia C, Aliberti S, Guiducci S, Russo E, Lari B, Grossi V, Infantino M, Manfredi M.   +12 more
europepmc   +1 more source

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease. [PDF]

Ther Adv Gastroenterol
Fousekis FS, Jefremow A, Katsanos KH, Neurath MF, Atreya R.   +4 more
europepmc   +1 more source

Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study). [PDF]

PLoS One
Akiyama M, Hidaka T, Kaneko M, Ito S, Taguchi H, Ishii T, Asai S, Hirata S, Ikeda K, Suzuki K, Kato N, Kaneko Y.   +11 more
europepmc   +1 more source